ArticleScientific reports2025
Neutrophil to albumin ratio predicts cardiovascular and all cause mortality in CVD patients with abnormal glucose metabolism.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Association of the neutrophil percentage-to-albumin ratio after endovascular treatment and 3-month clinical outcomes.Frontiers in neurologyTrial
- Albumin-Based Biomarkers and Adverse Outcomes in Coronary Artery Disease: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- Pan-immune inflammation value and neutrophil-to-albumin ratio predict hemorrhagic transformation after intravenous thrombolysis in acute ischemic stroke: a dual-center cohort study.Frontiers in nutrition · 2026Article
- Establishment and evaluation of a novel tool based on inflammation-nutrition derived biomarkers for early diagnosis of diabetic foot ulcers.Frontiers in immunology · 2026Article
- The combined association of the neutrophil percentage-to-albumin ratio (NPAR) and the uric acid-to-high-density lipoprotein cholesterol ratio (UHR) with adverse cardiac events in patients with chronic heart failure: a retrospective cohort study.Lipids in health and disease · 2025Article
- The Neutrophil-to-Albumin Ratio (NAR) Reflects the Severity of the Post-CABG Inflammatory Response and Is Associated with a Pre-Existing Pro-Inflammatory Monocyte Profile.Life (Basel, Switzerland) · 2025Article
- Machine learning-based predictive model for acute pancreatitis-associated lung injury: a retrospective analysis.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study examined the relationship between the neutrophil-to-albumin ratio (NPAR) and both all-cause and cardiovascular mortality in U.S. patients with cardiovascular disease (CVD) and abnormal glucose metabolism, using NHANES data from 1999 to 2018. Restricted cubic spline analysis identified a significant nonlinear association between NPAR and mortality (p < 0.001). Cox regression results showed that patients in the highest NPAR group (T3, ≥ 15.8) had higher risks of all-cause (HR 1.75, 95% CI 1.50-2.04) and cardiovascular mortality (HR 2.03, 95% CI 1.53-2.68) compared to the lowest group (T1, < 13.5), both with p < 0.0001. Kaplan-Meier survival curves confirmed greater mortality in the T3 group. Mediation analysis found that renal function, measured by eGFR, accounted for 14.49% of the effect on all-cause mortality and 13.38% on cardiovascular mortality. Among the 3163 participants, 1342 experienced all-cause deaths and 462 cardiovascular deaths. This study demonstrated a significant correlation of high NPAR and increased mortality in patients with abnormal glucose metabolism and CVD, suggesting that NPAR may represent a reliable predictor of mortality risk in this population, and emphasizing the importance of both inflammation and renal function monitoring.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.